Pharmaceuticals : Shots - Health News Pharmaceuticals
Stories About

Pharmaceuticals

"Everyone that's in there right now has probably done it," Clyde Polly says about Opana injections at his home. Seth Herald for NPR hide caption

toggle caption
Seth Herald for NPR

Inside A Small Brick House At The Heart Of Indiana's Opioid Crisis

  • Download
  • <iframe src="https://www.npr.org/player/embed/469525114/472553161" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Harvoni can cure hepatitis C, but the drug costs a fortune. Are loans to patients the answer? Lloyd Fox/Baltimore Sun/TNS via Getty Images hide caption

toggle caption
Lloyd Fox/Baltimore Sun/TNS via Getty Images

Valeant Pharmaceuticals has been the focus of a congressional investigation into high drug prices. . Michael Nagle/Bloomberg via Getty Images hide caption

toggle caption
Michael Nagle/Bloomberg via Getty Images
Katie Park/NPR

Cancer And Arthritis Drugs Drive Up Spending On Medicines

  • Download
  • <iframe src="https://www.npr.org/player/embed/470417680/470486343" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Erbitux is used to treat cancers that start in the head and neck and tumors there that spread from other parts of the body. Because its effectiveness varies, should the price also? Dr. P. Marazzi/Science Source hide caption

toggle caption
Dr. P. Marazzi/Science Source

Multiple sclerosis pill Tecfidera is on the top 10 list of most costly specialty drugs, as measured by overall spending, for California's health benefit system for public workers and retirees. John/Flickr hide caption

toggle caption
John/Flickr

Martin Shkreli was CEO of Turing Pharmaceuticals when the company boosted the price of a drug by 5,000 percent. He has since resigned. Paul Taggart/Bloomberg via Getty Images hide caption

toggle caption
Paul Taggart/Bloomberg via Getty Images

A 12-week regimen of Harvoni is 90 percent effective in curing an infection with hepatitis C, doctors say. It also costs about $95,000. Baltimore Sun/TNS via Getty Images hide caption

toggle caption
Baltimore Sun/TNS via Getty Images

States Deny Pricey Hepatitis C Drugs To Most Medicaid Patients

  • Download
  • <iframe src="https://www.npr.org/player/embed/460086615/461206268" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

A recent analysis by the Kaiser Family Foundation finds that Medicare recipients taking Revlimid for cancer could end up paying, on average, $11,538 out of pocket for the drug in 2016, even if the medicine is covered by their Medicare Part D plan. Carmine Galasso/MCT/Landov hide caption

toggle caption
Carmine Galasso/MCT/Landov